Cat allergy immunotherapy - Laboratorios Leti

Drug Profile

Cat allergy immunotherapy - Laboratorios Leti

Alternative Names: Allergenic cat epithelial extract - Laboratorios Leti

Latest Information Update: 29 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratorios LETI
  • Class Allergens; Antiallergics; Cat allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 04 Mar 2016 Immunogenicity and pharmacokinetics data from the in vitro studies were presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 01 Dec 2013 Laboratorios Leti completes a phase II trial in Hypersensitivity (cat allergy) in Spain (NCT01740024)
  • 01 Nov 2012 Phase-II clinical trials in Hypersensitivity (cat allergy) in Spain (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top